Natural Capsules Limited has informed the Exchange about General Updates
NATCAPSUQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 2.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved unaudited standalone and consolidated financial results for Q3 FY26 (quarter ended Dec 31, 2025). On a standalone basis, revenue from operations fell about 21% year-on-year to Rs. 3,414.64 lakhs (vs Rs. 4,341.18 lakhs in Q3 FY25), and net profit dropped nearly 79% to Rs. 36.23 lakhs. On a consolidated basis, revenue declined about 14% YoY to Rs. 3,774.56 lakhs and the company swung to a net loss of Rs. 911.71 lakhs for the quarter, taking the nine-month consolidated loss to Rs. 1,968.66 lakhs, largely driven by heavy losses in the API segment. The company also disclosed that subsidiary Natural Biogenex started commercial operations only in March 2025 and has not yet reached full revenue potential, and that one manufacturing unit was shut from Dec 26 to Jan 30 due to a regulatory issue. Additionally, 45,000 equity shares were allotted under ESOP to an ex-employee, raising paid-up capital to Rs. 10.38 crore, and a postal ballot was approved to enhance the Section 186 lending/investment limit. The auditor issued an unmodified limited review conclusion.
Sharp deterioration in profitability, especially at the consolidated level where the API segment is bleeding, is likely to weigh on the stock. The manufacturing unit shutdown and subsidiary ramp-up risks add to near-term uncertainty despite a clean auditor report.